Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Malignant Glioma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Malignant Glioma - Pipeline Review, H2 2014', provides an overview of the Malignant Glioma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Glioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Malignant Glioma Overview 7 Therapeutics Development 8 Pipeline Products for Malignant Glioma - Overview 8 Pipeline Products for Malignant Glioma - Comparative Analysis 9 Malignant Glioma - Therapeutics under Development by Companies 10 Malignant Glioma - Therapeutics under Investigation by Universities/Institutes 11 Malignant Glioma - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Malignant Glioma - Products under Development by Companies 15 Malignant Glioma - Products under Investigation by Universities/Institutes 16 Malignant Glioma - Companies Involved in Therapeutics Development 17 Advantagene, Inc. 17 Eli Lilly and Company 18 Lipopharma Therapeutics SL 19 Nuo Therapeutics, Inc. 20 Orbus Therapeutics, Inc. 21 Sanofi 22 Stemline Therapeutics, Inc. 23 ZIOPHARM Oncology, Inc. 24 Malignant Glioma - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 Ac-929C - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Ad-RTS-IL-12 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 ALD-451 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Dendritic Cell Therapy for Malignant Gliomas - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Dendritic Cell Therapy for Oncology - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Dendritic Cell Therapy for Oncology - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Dendritic Cell Therapy for Oncology - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 eflornithine hydrochloride - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 galunisertib - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 GliAtak - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 IDD-004 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 LD-224 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Minerval - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Oncolytic Virus for Oncology - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 SL-701 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Vaccine to Target Survivin for Malignant Glioma - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 voxtalisib - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 WT-1 Peptide Vaccine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Malignant Glioma - Recent Pipeline Updates 61 Malignant Glioma - Dormant Projects 67 Malignant Glioma - Discontinued Products 68 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 70 Disclaimer 70
List of Tables Number of Products under Development for Malignant Glioma, H2 2014 8 Number of Products under Development for Malignant Glioma - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Malignant Glioma - Pipeline by Advantagene, Inc., H2 2014 17 Malignant Glioma - Pipeline by Eli Lilly and Company, H2 2014 18 Malignant Glioma - Pipeline by Lipopharma Therapeutics SL, H2 2014 19 Malignant Glioma - Pipeline by Nuo Therapeutics, Inc., H2 2014 20 Malignant Glioma - Pipeline by Orbus Therapeutics, Inc., H2 2014 21 Malignant Glioma - Pipeline by Sanofi, H2 2014 22 Malignant Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2014 23 Malignant Glioma - Pipeline by ZIOPHARM Oncology, Inc., H2 2014 24 Assessment by Monotherapy Products, H2 2014 25 Number of Products by Stage and Target, H2 2014 27 Number of Products by Stage and Mechanism of Action, H2 2014 29 Number of Products by Stage and Route of Administration, H2 2014 31 Number of Products by Stage and Molecule Type, H2 2014 33 Malignant Glioma Therapeutics - Recent Pipeline Updates, H2 2014 61 Malignant Glioma - Dormant Projects, H2 2014 67 Malignant Glioma - Discontinued Products, H2 2014 68
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.